Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial.
Sibylle LoiblDenise TreueJan BudcziesKarsten WeberAlbrecht StenzingerWolfgang Daniel SchmittWilko WeichertPaul JankJenny FurlanettoFrederick KlauschenThomas KarnNicole PfarrGunter von MinckwitzMarkus MöbsChristian JackischChristine SersAndreas SchneeweissPeter Andreas FaschingChristian SchemMichael HummelMarion van MackelenberghValentina NekljudovaMichael UntchCarsten DenkertPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2019)
High genetic heterogeneity was observed in different breast cancer subtypes. Our study shows that FFPE-based NGS can be used to identify markers of therapy resistance in clinical study cohorts. PIK3CA mutations could be a major mediator of therapy resistance in breast cancer.